[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480619":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":38,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Reproductive Medicine Associates of New Jersey","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","ACTIVE_COMPARATOR","an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group",[13],"Other: Platelet Rich Plasma Intrauterine infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","PLACEBO_COMPARATOR","an intrauterine infusion of normal saline will be administered to this group",[19],"Other: Normal saline Intrauterine infusion",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Platelet Rich Plasma Intrauterine infusion","an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Normal saline Intrauterine infusion","an intrauterine infusion of normal saline will be administered to this group of participants",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Christine V Whitehead, BSN, RN","CONTACT","19736562841","clinicalresearchteam@ivirma.com",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":35},"Caroline Zuckerman, BS",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-74.54932,40.70621,{"lat":50,"lon":49},[53,55,56],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":54},"cwhitehead@ivirma.com",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":57,"role":58,"phone":25,"phoneExt":25,"email":25},"Jason Franasiak, MD","PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100480619","platelet-rich-plasma-for-insufficient-endometrium-100480619",false,"NCT05538338","Platelet Rich Plasma for Insufficient Endometrium","Intrauterine Platelet Rich Plasma (PRP) Infusion for Endometrial Insufficiency: A Prospective, Double-Blind, Placebo-Controlled Randomized Controlled Trial","PIER","Inclusion Criteria:\n\n* Patients who have previously undergone at least 2 unsuccessful frozen embryo transfer cycles, defined as failure to achieve a sustained clinical pregnancy (visualization of intrauterine gestational sac on ultrasound or a cancelled embryo transfer cycle due to inadequate endometrial thickness\n* Patients with a diagnosis of thin endometrial lining (less than or equal to 6 mm maximum thickness) during prior unsuccessful or canceled embryo transfer cycles.\n\nExclusion Criteria:\n\n* Fewer than 2 prior unsuccessful or canceled frozen embryo transfer cycles.\n* Most recent unsuccessful embryo transfer prior to January 1, 2017.\n* Mullerian anomalies, excluding arcuate uterus\n* Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery\n* Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.\n* Failure of patient to agree to enrollment in study with written consent.\n* Concurrent pregnancy\n* Anticoagulation use for which plasma infusion is contraindicated\n* History of thrombosis\n* Thrombophilia either inherited or acquired\n* Concomitant use of adjunctive therapies for proliferation. These must be discontinued upon enrollment.\n* Embryo planned to be used for transfer generated from surgically obtained sperm due to a diagnosis of non-obstructive azoospermia\n* Recurrent\u002Fpersistent endometrial fluid in prior cycles","FEMALE","18 Years","45 Years",{"count":73,"type":74},62,"ESTIMATED","INTERVENTIONAL",[77],"NA","To determine the effectiveness of an intrauterine PRP infusion on endometrial thickness and in vitro fertilization (IVF) outcomes in a population of infertile women with a history of unresponsive thin endometrium.",[80],"Infertility of Uterine Origin","2026-06-01",{"date":83,"type":84},"2026-06-03","ACTUAL",{"date":86,"type":84},"2022-10-15",{"date":88,"type":74},"2027-12",{"name":5,"class":6},1]